Phages Reveal a Vulnerable Switch in the Bacterial Cell Wall

The threat of drug-resistant bacteria is often described as a race between drug development and microbial evolution. A new clue comes from an unexpected teacher: phages, the viruses that specialize in infecting bacteria. According to a study by a California Institute of Technology team published in Nature, several viral proteins with no obvious close relationship to one another can all trap the MurJ protein, which bacteria need to build their cell walls, in the same conformation. That stalls cell-wall construction and ultimately leads to bacterial death.

MurJ is a “flippase” on the bacterial inner membrane, responsible for moving peptidoglycan precursors from the inside of the cell to the outside so they can be added to the growing cell wall. Peptidoglycan is a key material that helps many bacteria maintain their shape and resist osmotic pressure. Human cells do not have this structure, so it has long been an important focus for antibiotic development. Penicillin and related drugs have already shown that interfering with cell-wall construction can effectively kill bacteria; this study shifts attention to an earlier, more internal transport step.

The team focused on single-gene lysis proteins used by small phages to rupture their hosts, abbreviated in English as Sgl. Using cryo-electron microscopy, the researchers resolved high-resolution structures of MurJ bound to different Sgl proteins. They found that SglM, SglPP7, and the newly identified SglCJ3 all insert into a groove in MurJ, leaving the protein in an outward-facing open state. For a transport protein that must switch conformations between the inner and outer sides, this is equivalent to applying a mechanical brake.

What gives this finding real weight is not merely that “a protein attacked by viruses has been found,” but that different viruses appear to have independently evolved similar strategies. This convergent evolution suggests that MurJ may be one of the few positions in bacterial physiology that is both essential and precisely targetable. If phages in nature repeatedly choose the same weakness, drug developers have reason to study carefully whether it can be mimicked by small molecules or other therapeutic designs.

However, this is still mainly a result of basic research and structural biology, not the arrival of a new antibiotic. Public information shows that the study demonstrated how phage proteins inhibit MurJ and provided a possible design blueprint; but turning the conformation in which a protein binds its target into a drug that can enter the human body, reliably reach the site of infection, and avoid rapidly inducing resistance will still require compound screening, activity testing, toxicity assessment, and animal or clinical studies.

The finding also reminds people that the problem of drug resistance may not have to be addressed only by modifying existing drugs. Phages and bacteria have been battling for a long time, and nature has already tested many antibacterial strategies. Dissecting those strategies at atomic scale may point antibiotic research toward new entry points. Whether this can change the treatment landscape for superbugs cannot yet be concluded; but MurJ, this cell-wall switch repeatedly locked by viruses, has become a clear candidate target worthy of the next round of experiments.